Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Tumor endothelial marker 1–specific DNA vaccination targets tumor vasculature
John G. Facciponte, … , George Coukos, Andrea Facciabene
John G. Facciponte, … , George Coukos, Andrea Facciabene
Published March 18, 2014
Citation Information: J Clin Invest. 2014;124(4):1497-1511. https://doi.org/10.1172/JCI67382.
View: Text | PDF
Research Article Oncology Article has an altmetric score of 77

Tumor endothelial marker 1–specific DNA vaccination targets tumor vasculature

  • Text
  • PDF
Abstract

Tumor endothelial marker 1 (TEM1; also known as endosialin or CD248) is a protein found on tumor vasculature and in tumor stroma. Here, we tested whether TEM1 has potential as a therapeutic target for cancer immunotherapy by immunizing immunocompetent mice with Tem1 cDNA fused to the minimal domain of the C fragment of tetanus toxoid (referred to herein as Tem1-TT vaccine). Tem1-TT vaccination elicited CD8+ and/or CD4+ T cell responses against immunodominant TEM1 protein sequences. Prophylactic immunization of animals with Tem1-TT prevented or delayed tumor formation in several murine tumor models. Therapeutic vaccination of tumor-bearing mice reduced tumor vascularity, increased infiltration of CD3+ T cells into the tumor, and controlled progression of established tumors. Tem1-TT vaccination also elicited CD8+ cytotoxic T cell responses against murine tumor-specific antigens. Effective Tem1-TT vaccination did not affect angiogenesis-dependent physiological processes, including wound healing and reproduction. Based on these data and the widespread expression of TEM1 on the vasculature of different tumor types, we conclude that targeting TEM1 has therapeutic potential in cancer immunotherapy.

Authors

John G. Facciponte, Stefano Ugel, Francesco De Sanctis, Chunsheng Li, Liping Wang, Gautham Nair, Sandy Sehgal, Arjun Raj, Efthymia Matthaiou, George Coukos, Andrea Facciabene

×

Figure 2

Characterization of TEM1 immunodominant epitopes.

Options: View larger image (or click on image) Download as PowerPoint
Characterization of TEM1 immunodominant epitopes.
(A and B) Specific pep...
(A and B) Specific peptide pools restricted in H-2d (A) and H-2b (B) haplotypes. 1 × 106 splenocytes from BALB/c (A) or C57BL/6 (B) mice vaccinated with Tem1-TT were cultured with the 4 TEM1 peptide pools and tested by ELISpot and ICS for IFN-γ secretion. (A) Splenocytes from Tem1-TT–vaccinated BALB/c mice recognized pool C (left), which induced CD3+CD4+ (middle) and CD3+CD8+ (right) T cell responses. (B) Splenocytes from Tem1-TT–vaccinated C57BL/6 mice recognized pool D (left). By ICS, there was a specific CD3+CD8+ response (right). Data are mean ± SD (n = 5 per group) from 1 of 3 experiments. (C and D) Characterization of TEM1-derived peptides specific for H-2d (C) and H-2b (D) haplotypes. Peptides from pool C (C) or pool D (D) were divided into 7 minipools of 15 mers, so each individual peptide was present in 2 minipools and could be identified through an experimental matrix design. (C) Reactivity to pool C was present in minipools f, g, and 5. (D) Reactivity to pool D was present in minipools a and 6. Data are from 1 of 3 independent experiments. (E) TEM1696–710 induced IFN-γ secretion and cytotoxic effector activity. Splenocytes from TT-, Tem1-, or Tem1-TT–vaccinated mice was used in peptide-stimulated cultures and tested in an IFN-γ secretion ELISA (left) and CTL assay (right). Tem1-TT exclusively primed and expanded antigen-specific CD8+ T cells that killed ECs in the context of MHC class I/TEM1696–710 peptide, but not control peptides.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Picked up by 8 news outlets
Blogged by 3
Posted by 5 X users
Referenced in 2 patents
Mentioned by 1 weibo users
82 readers on Mendeley
See more details